Brand: nanjian
Model: 148031-34-9
Min. Order: 10mg
Product Name:Eptifibatide
Sequence:Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2
Cas No.:148031-34-9
Molecular Formula:C35H49N11O9S2
Molecular Weight:832.4
Appearance:White slightly yellwish powder
Specific Rotation[20/D] :-75.0～-95.0°（C=1, 1%HAc）
Amino Acids composition :± 10%
Peptide Purity (By HPLC):≥98% by area integration
Related Substance (By HPLC):Total Impurities (%)≤2.0% Largest Single Impurity (%):≤ 1.0%
Water Content (Karl Fischer):≤8.0%
Peptide Content(N determination):≥80%
Acetate Content :≤15%
IR spectrum :in accordance
Delivery: EMS, DHL, TNT, FedEx, UPS
Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).

Brief introduction:
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).

It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Indications:
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Contraindications and precautions

Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μl because no clinical experience exists regarding such patients.

Renal insufficiency :

Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.

Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.

Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards.

Allergy to eptifibatide and/or other ingredients.

Severe, uncontrolled hypertension.

Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.

Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.

Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.

Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists